Rafael Holdings, Inc. RFL Accrued Clinical Trial Expense
Accrued Clinical Trial Expense at other companies
Other financials
Where this comes from
Reported directly by Rafael Holdings, Inc. in its filing.
Tagged under the XBRL concept rfl:AccruedClinicalTrialExpense.
The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rafael Holdings, Inc.'s accrued clinical trial expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rafael Holdings, Inc.'s accrued clinical trial expense?
- Rafael Holdings, Inc. (RFL) reported accrued clinical trial expense of $381K in Q1 2026.
- What does accrued clinical trial expense mean?
- The estimated liability for clinical trial services performed by third-party research organizations that have not yet been invoiced or paid. This is a vital metric for pharmaceutical companies to track the true cost of R&D progress. It provides visibility into the upcoming cash requirements for ongoing drug development programs.